ReviewBMC pulmonary medicine2016
Cystic fibrosis lung environment and Pseudomonas aeruginosa infection.
Review in BMC pulmonary medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 226 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
226 citing papers in PubMed, 1 synthesis or guideline pooled it, 373 citations in OpenAlex.
- Meta-analysis Reveals Potential Influence of Oxidative Stress on the Airway Microbiomes of Cystic Fibrosis Patients.Genomics, proteomics & bioinformatics · 2019Pooled it
- Smaller Genomes and Shorter Prophage Sequences Differentiate Clinical from Environmental Isolates ofbioRxiv : the preprint server for biology · 2026Article
- Article
- Combined Marbofloxacin-Geraniol-Tris-EDTA Exposure Delays Marbofloxacin Resistance Escalation inAntibiotics (Basel, Switzerland) · 2026Article
- Mucin-induced metabolic reprogramming inmSystems · 2026Article
- Biological and clinical significance of iron inJournal of bacteriology · 2026Review
- Host, Pathogen, and Pulmonary Anatomy in Pneumonia: An Integrated Imaging and Clinical Perspective.Diagnostics (Basel, Switzerland) · 2026Review
- Cytokine and chemokine dysregulation by microbial biofilm components: mechanisms and clinical implications.Archives of microbiology · 2026Review
- Exploring the Role ofACS infectious diseases · 2026Article
- Treatment of Pseudomonas by Removal of Cloaking Antibodies: Is Common Polysaccharide Antigen a Factor?The Journal of infectious diseases · 2026Article
- Prevalence of Pseudomonas aeruginosa in Australian wild birds, native wildlife, livestock and domestic animals.Scientific reports · 2026Article
- A longitudinal evaluation of localised chronic Pseudomonas aeruginosa infection in cystic fibrosis rat models.BMC microbiology · 2026Article
- Evolutionary adaptations ofMicrobiology spectrum · 2026Article
- Exploring the anti-biofilm effect of darobactin B and colistin in static and dynamic environments.Microbiology spectrum · 2026Article
- Phage-Mediated Iron Acquisition bybioRxiv : the preprint server for biology · 2026Article
- Identifying Pathoadaptation inACS sensors · 2026Article
- Steering the course: targeting and exploiting surface receptors in phage therapy.Journal of bacteriology · 2026Review
- Mutations in filamentous bacteriophages spark eco-evolutionary feedbacks in Pseudomonas aeruginosa.The ISME journal · 2026Article
- Comparative immunogenicity and protective efficacy of BECC438 and BECC470 adjuvants in a vaccine formulation againstFrontiers in immunology · 2026Article
- The longitudinal expression ofMicrobiology (Reading, England) · 2026Article
166 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe airways of patients with cystic fibrosis (CF) are highly complex, subject to various environmental conditions as well as a distinct microbiota. Pseudomonas aeruginosa is recognized as one of the most important pulmonary pathogens and the predominant cause of morbidity and mortality in CF. A multifarious interplay between the host, pathogens, microbiota, and the environment shapes the course of the disease. There have been several excellent reviews detailing CF pathology, Pseudomonas and the role of environment in CF but only a few reviews connect these entities with regards to influence on the overall course of the disease. A holistic understanding of contributing factors is pertinent to inform new research and therapeutics. DISCUSSION: In this article, we discuss the deterministic alterations in lung physiology as a result of CF. We also revisit the impact of those changes on the microbiota, with special emphasis on P. aeruginosa and the influence of other non-genetic factors on CF. Substantial past and current research on various genetic and non-genetic aspects of cystic fibrosis has been reviewed to assess the effect of different factors on CF pulmonary infection. A thorough review of contributing factors in CF and the alterations in lung physiology indicate that CF lung infection is multi-factorial with no isolated cause that should be solely targeted to control disease progression. A combinatorial approach may be required to ensure better disease outcomes.
conclusionCF lung infection is a complex disease and requires a broad multidisciplinary approach to improve CF disease outcomes. A holistic understanding of the underlying mechanisms and non-genetic contributing factors in CF is central to development of new and targeted therapeutic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.